Royal Visit for Malvern Panalytical to celebrate key role in vaccine development

Malvern Panalytical

Malvern Panalytical, the analytical systems manufacturer and contract services provider, welcomed His Royal Highness The Earl of Wessex to its Worcestershire headquarters.

Malvern Panalytical was selected for the Royal visit, amongst a small number of other Worcestershire businesses, primarily because of its scientific and technical contribution to the development of medicines and vaccines to treat and prevent COVID-19.

Andrew Heath – Chief Executive of Spectris plc which owns Malvern Panalytical, said: “It has been our pleasure to welcome Prince Edward to our Malvern development and manufacturing facility and to explain how Malvern Panalytical’s people, products and services are assisting the global effort to fight COVID-19. We are immensely proud of the role the team here is playing in applying its technical and scientific expertise to help alleviate this humanitarian crisis.”

His Royal Highness was introduced to a number of Malvern Panalytical employees from across the business during his walk through the facility, learning about the roles they play in the development of new technologies and services. Also on display were a number of the scientific instruments used by Malvern Panalytical’s pharmaceutical customers in developing and manufacturing new drugs and vaccines, including the Zetasizer Advance light scattering range, Morphologi 4 analytical imaging systems, OMNISEC size exclusion chromatography instruments and NanoSight nanoparticle tracking analysis platforms.

The vital role science has played in the fight against COVID-19 is clear. Malvern Panalytical is proud to play a key role in the global effort to develop treatments and vaccines, providing analytical instruments and expert support to SARS-CoV-2 vaccine labs across the globe.

Mark Fleiner – President, Malvern Panalytical, added: “Throughout 2020 and 2021, we have witnessed our analytical systems and services make a real contribution to the development of protein antigen and mRNA-based COVID-19 vaccines, as well as to the development of antiviral drugs. Malvern Panalytical provides the instruments and expertise to support robust and rapid vaccine development and assist pharmaceutical organizations in assuring the quality of vaccines and other treatments.”

“It makes us proud to see how we are helping our customers create a better world in all sorts of markets. From renewable energy and sustainable building materials, all the way through to nutritious foods and critically important medicines, Malvern Panalytical is making a positive impact.”